ES2551708T3 - Compuestos de 4-desdimetilamino tetraciclina - Google Patents

Compuestos de 4-desdimetilamino tetraciclina Download PDF

Info

Publication number
ES2551708T3
ES2551708T3 ES10183340.8T ES10183340T ES2551708T3 ES 2551708 T3 ES2551708 T3 ES 2551708T3 ES 10183340 T ES10183340 T ES 10183340T ES 2551708 T3 ES2551708 T3 ES 2551708T3
Authority
ES
Spain
Prior art keywords
dedimethylamino
mmol
added
reaction
filtered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10183340.8T
Other languages
English (en)
Inventor
Mark L. Nelson
Kwasi Ohemeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2551708T3 publication Critical patent/ES2551708T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2475—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aralkylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Un compuesto de tetraciclina sustituido seleccionado del grupo que consiste de**Fórmula** y sales farmacéuticamente aceptables de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
E10183340
28-10-2015
30.0 mL de ácido sulfúrico concentrado se agrega a 1.00 g de 4-desdimetilamino sanciclina con agitación y la solución luego se enfría a 0° C. Se agrega 1.09g de N-yodosuccinimida en forma de porciones a la solución durante una hora y la mezcla de reacción se monitorea por HPLC y TLC. La mezcla de reacción se vierte en 250 mL de agua helada, y se extrae tres veces con n-butanol, y el solvente se elimina bajo presión reducida. El residuo crudo se purifica mediante HPLC preparativo proporcionando 7-yodosanciclina y 7,9-diiodosanciclina.
7,9-Bis(3,4-Metilenodioxifenil)-Sanciclina
imagen19
Esquema 20
0.74 mmol de 7,9-diyodo 4-desdimetilamino sanciclina (20C) y 8.3 mg (0.37 mmol) acetato de paladio se disuelven
10 en 25 ml de metanol, bajo una atmósfera de nitrógeno. La solución se calienta a 60° C. Después de agitación durante diez minutos se agrega 234 mg (2.22 mmol), carbonato de sodio seguido por 246 mg (1.48 mmol) de ácido 3,4-metilenodioxifenil borónico (20B). Después de que se completa la reacción, la mezcla de reacción se filtra a través de un lecho de celita y se concentra bajo presión reducida. Este producto crudo se purifica mediante cromatografía líquida preparativa utilizando una fase estacionaria C18 con un eluyente A: 0.1 % de TFA en agua y
15 eluyente B: 0.1 % de TFA en acetonitrilo.
7 Yodo 4-Desdimetilamino Sanciclina
Un gramo de 4-desdimetilamino sanciclina se disuelve en 25 mL de TFA (ácido trifluoroacético) que se enfría a 0 C (en hielo). Se agrega 1.2 equivalentes de N-yodosuccinimida (NIS) a la mezcla de reacción y se hace reaccionar durante cuarenta minutos. La reacción se elimina del baño helado y luego se deja reaccionar a temperatura 20 ambiente durante unas cinco horas adicionales. La mezcla luego se analiza mediante HPLC y TLC, se lleva a terminación mediante la adición en forma de etapas de NIS. Después de la terminación de la reacción, el TFA se elimina en vacío y 3 mL de MeOH se agrega para disolver el residuo. La solución metanólica luego se agrega lentamente a una solución rápidamente agitada de éter de dietilo para formar un precipitado. El isómero 7-yodo de sanciclina se purifica al tratar el producto de 7-yodo con carbón activado, se filtra a través de Celita, y se elimina
25 posteriormente el solvente en vacío para producir el compuesto isómero 7 como un sólido puro.
7-Tetrametilsililetinil-4-Desdimetilamino Sanciclina
imagen20
Esquema 21
A una solución de 10 mmol de trifluoroacetato de 7-yodo-4-desdimetilamino-sanciclina 500 mg de tetrakis30 trifenilfosfino-paladato, 500 mg yoduro de cobre (I), 100 mg de acetato de paladio y 30 mL de trietilamina se agrega 3 ml de trimetilsililacetileno. La mezcla de reacción se agita a temperatura ambiente durante dos horas luego se filtra
20
imagen21
E10183340
28-10-2015
7-Etil-4-desdimetilamino sanciclina (23B, 6.7 mmol, 3.2 g) se disuelve en 75 ml de ácido metanosulfónico a temperatura ambiente. Se agrega N-yodo succinimida (24B, 13.5 mmol, 3.05 g) durante dos horas en 6 porciones. Después de dos horas se agrega éter de dietilo, y el precipitado se filtra y se seca. El producto crudo se purifica mediante cromatografía líquida preparativa utilizando una fase estacionaria C18 con eluyente A: 0.1% de TFA en agua y eluyente B: 0.1% de TFA en acetonitrilo.
7-Etil-9-Ciclohexeniletinil-4-Desdimetilamino Sanciclina
imagen22
Esquema 25
A una solución de 7-etil-4-desdimetilamino sanciclina (1.13 mmol), 50 mg de tetrakis-trifenilfosfino-paladato, 50 mg
10 de yoduro de cobre (I), 10 mg de acetato de paladio y 3 ml de trietilamina se agrega 0.1 ml de ciclohexenil-acetileno. La mezcla de reacción se agita a 60° C durante una hora, se filtra a través de un lecho de celita y se concentra. El material seco se disuelve en metanol y se filtra. La solución luego se concentra y se purifica utilizando cromatografía líquida preparativa. La cromatografía líquida preparativa utiliza una fase estacionaria C18 con eluyente A: 0.1% de TFA en agua y eluyente B: 0.1% de TFA en acetonitrilo.
15 7-Yodo-9-t-Butil-4-Desdimetilamino Sanciclina
imagen23
Esquema 26
9-t-butil-4-desdimetilamino sanciclina (26A, 1.13 g, 2 mmol) se disuelve en 5 ml de ácido metanosulfónico (0.448, 2 mmol). Se agrega N-yodosuccinimida (26B) a temperatura ambiente durante una hora en cuatro porciones. El 20 producto (26C) se precipita con éter de dietilo, se filtra y se utiliza en otra reacción sin purificación adicional.
7-(2-Metoxi-5-Dimetilaminometilfenil)-9-t-Butil-4-Desdimetilamino Sanciclina
imagen24
Esquema 27
7-Yodo-9-t-butil-4-desdimetilamino sanciclina (26B, 710 mg, 1.0 mmol) y acetato de paladio (22.4 mg, 0.1 mmol) se
25 disuelven en 25 ml de metanol bajo una atmósfera de nitrógeno. Se agregan carbonato de cesio (3.25 g, 10 mmol) y ácido 2-metoxi-5-dimetilaminometilfenil-borónico (27B, 0.435 g, 0.15 mmol). La mezcla de reacción se agita a 60 °C durante dos horas y luego se filtra a través de un lecho de celita y se concentra bajo presión reducida. El producto
22
5
10
15
20
25
30
35
E10183340
28-10-2015
crudo se purifica mediante cromatografía líquida preparativa utilizando una fase estacionaria C18 en eluyente A: 0.1% de TFA en agua y eluyente B: 0.1% de TFA en acetonitrilo.
Ejemplo de referencia 3: Preparación de compuestos de 4-desdimetilamino tetraciclina 9-sustituida
Preparación de 9-yodo 4-desdimetilamino minociclina
A 200 ml de 97% de ácido metanosulfónico se agrega lentamente, a temperatura ambiente, en forma de porciones
[56.56 mM] de sal de clorhidato de 4-desdimetilamino minociclina. La solución oscura luego se agita a temperatura ambiente mientras que se agrega [38 g; 169.7 mM] de N-yodosuccinimida, en seis porciones iguales durante un tiempo de 3.0 horas. La reacción se monitorea a través de LC analítico, observando la desaparición del material de partida.
La reacción se detiene lentamente en 2L de agua enfriada con hielo que contiene [17.88 g; 1134.1 mM] de tiosulfato de sodio con agitación rápida. Este enfriamiento se agita durante aproximadamente 30 minutos a temperatura ambiente. La capa acuosa luego se extrae con 6x200ml de acetato de etilo antes la capa acuosa se vertió sobre
[259.8 g; 3.08 M] de hidrógeno carbonato de sodio que contiene 300 ml de n-butanol. Las fases se separan y la fase acuosa se extrae con 4x250ml de n-butanol. Las fracciones orgánicas se combinan y se lavan con 3x250ml de agua y una vez con 250 ml de solución salina saturada. La fase orgánica resultante se reduce hasta sequedad bajo presión reducida. El residuo se suspende en metanol (~ 600 ml) y el gas HCl anhidro se burbujea en esta mezcla hasta que ocurre la solución. Esta solución se reduce hasta sequedad bajo presión reducida. Los filtrados se reducen a sequedad bajo presión reducida. El material resultante se tritura con 300 ml de éter de metilo y t-Butilo se aísla mediante filtración. Este material se vuelve a disolver en 300 ml de metanol y se trata con 0.5 g de carbón de madera, se filtra y los filtrados se reducen hasta sequedad bajo presión reducida. El material es de nuevo en forma de polvo bajo metil t-butil éter, aislado mediante filtración por succión y se lava adicionalmente con éter, y finalmente con hexanos. El material se seca al vacío para dar el producto.
Procedimiento general para la preparación de Compuestos de 9-alquinil 4-desdimetilamino minociclina
1 mmol de 9-yodo 4-desdimetilamino minociclina, 50 mg de tetrakis trifenilfosfinato paladato, 12 mg de acetato de paladio, 32 mg de yoduro de cobre (I) se disuelven/suspenden en 10 ml de acetonitrilo. Se agregan 2 a 5 mL de trietilamina y 3 a 5 mmol de derivado de alquinil 4-desdimetilamino minociclina. La mezcla de reacción se agita vigorosamente entre temperatura ambiente a 70° C. El tiempo de reacción es 2-24 horas. Cuando la reacción se completa la suspensión oscura se filtra a través de un lecho de celita y se concentra. El producto crudo se purifica mediante HPLC prep. Las fracciones combinadas se concentran y toman en ~1 ml de metanol. Se agrega ~3 ml de HCl metanol saturado, y el producto se precipita con éter.
Procedimiento General para la Preparación de Compuestos de 9-Aril 4-Desdimetilamino Minociclina
0.15 mmol de 9-yodo 4-desdimetilamino minociclina, PdOAc (3.2mg), 229 µl de Na2CO3 2M y 2 equivalentes de ácido fenil borónico se disuelven/suspenden en 10 ml de metanol. El matraz de reacción se purga con argón y la reacción se corren durante un mínimo de cuatro horas o hasta que el monitoreo de HPLC muestra el consumo del material de partida y/o la aparición de productos. La suspensión se filtra a través de celita, y se somete a purificación mediante HPLC prep sobre una columna de divinilbenceno.
9-(4-Trifluorometoxifenilureido)-Metil Minociclina
imagen25
Esquema 28
23
imagen26

Claims (1)

  1. imagen1
ES10183340.8T 2002-01-08 2003-01-06 Compuestos de 4-desdimetilamino tetraciclina Expired - Lifetime ES2551708T3 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US34695602P 2002-01-08 2002-01-08
US34693002P 2002-01-08 2002-01-08
US34692902P 2002-01-08 2002-01-08
US34706502P 2002-01-08 2002-01-08
US347065P 2002-01-08
US346929P 2002-01-08
US346956P 2002-01-08
US346930P 2002-01-08
US36704902P 2002-03-21 2002-03-21
US367049P 2002-03-21

Publications (1)

Publication Number Publication Date
ES2551708T3 true ES2551708T3 (es) 2015-11-23

Family

ID=27541208

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10183340.8T Expired - Lifetime ES2551708T3 (es) 2002-01-08 2003-01-06 Compuestos de 4-desdimetilamino tetraciclina

Country Status (6)

Country Link
US (4) US7056902B2 (es)
EP (7) EP2311796A1 (es)
JP (4) JP2005514410A (es)
AU (1) AU2003235759A1 (es)
ES (1) ES2551708T3 (es)
WO (1) WO2003057169A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756365B2 (en) * 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US8106225B2 (en) * 1999-09-14 2012-01-31 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
PT1240133E (pt) * 1999-09-14 2006-07-31 Tufts College Processos para preparar tetraciclinas substituidas com quimicas baseadas em metais de transicao
CA2397863A1 (en) 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
WO2001074761A1 (en) * 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US6642270B2 (en) * 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
US20040224927A1 (en) * 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
WO2001098236A2 (en) * 2000-06-16 2001-12-27 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
SI1301467T1 (sl) 2000-07-07 2007-02-28 Tufts College 9-substituirane minociklinske spojine
IL153672A0 (en) * 2000-07-07 2003-07-06 Tufts College 7-substituted tetracycline compounds
US7094806B2 (en) * 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
AU2002250331A1 (en) * 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
EP1368305B1 (en) 2001-03-13 2008-08-13 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
WO2002072031A2 (en) 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
JP2004537544A (ja) * 2001-07-13 2004-12-16 パラテック ファーマシューティカルズ インコーポレイテッド 標的治療活性を有するテトラサイクリン化合物
WO2003055441A2 (en) 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
ES2551708T3 (es) * 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
EP1482926A4 (en) * 2002-03-08 2006-04-12 Paratek Pharm Innc AMINO METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003079984A2 (en) * 2002-03-21 2003-10-02 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EA200900540A1 (ru) * 2002-07-12 2009-12-30 Пэрэтек Фамэсьютикэлс, Инк. Замещённые соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
CA2503446C (en) * 2002-10-24 2012-12-18 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
EP1648859B1 (en) 2003-07-09 2013-02-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US7786099B2 (en) 2004-01-15 2010-08-31 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
US7807842B2 (en) 2004-05-21 2010-10-05 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
AU2012202559B2 (en) * 2004-05-21 2014-07-17 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
AU2014250722B2 (en) * 2004-05-21 2016-05-26 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
TWI261038B (en) * 2004-08-11 2006-09-01 Bo-Cheng Chen Bicycle gear-shifting handgrip
WO2006047671A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269991A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2006084265A1 (en) * 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-DERIVATIVES OF TETRACYCLINE COMPOUNDS
AR057032A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Tigeciclina y metodos de preparacion
AR057033A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Tigeciclina y metodos para preparar 9-nitrominociclina
JP2009502809A (ja) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法
BRPI0620430A2 (pt) * 2005-12-22 2011-11-08 Wyeth Corp métodos para tratar infecções do trato gastrointestinal com tigeciclina
CN101340895A (zh) * 2005-12-22 2009-01-07 惠氏公司 包含替加环素的口服制剂
US9078811B2 (en) * 2006-01-24 2015-07-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2016044B1 (en) 2006-04-07 2020-06-10 President and Fellows of Harvard College Pentacycline derivatives for the treatment of infections
CA2652347A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
EP2479169B1 (en) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthesis of Enone Intermediate
PT2120963T (pt) * 2006-12-21 2018-12-17 Paratek Pharm Innc Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
EP2450347B1 (en) * 2006-12-21 2015-06-24 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2008127722A1 (en) * 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
BRPI0819696B1 (pt) 2007-11-29 2018-10-23 Actelion Pharmaceuticals Ltd compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
US20090253660A1 (en) 2008-03-05 2009-10-08 Paratek Pharmaceuticals, Inc. Minocycline Compounds and Methods of Use Thereof
JP2011517697A (ja) * 2008-04-14 2011-06-16 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
CA2730377C (en) 2008-07-11 2017-09-19 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
US20100190755A1 (en) * 2008-09-19 2010-07-29 Paul Abato Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
WO2010126607A2 (en) 2009-04-30 2010-11-04 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
WO2010129057A2 (en) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
SMT201900096T1 (it) 2012-08-31 2019-02-28 Tetraphase Pharmaceuticals Inc Composti di tetracicline
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
SG10201913599RA (en) 2016-11-01 2020-02-27 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
EP4117671A4 (en) * 2020-03-10 2024-04-10 Texas Tech University System NEW MODIFIED TETRACYCLINES FOR THE TREATMENT OF ALCOHOL ABUSE, PAIN AND OTHER DISEASES WITH POTENTIAL INFLAMMATORY PROCESSES
IL304921A (en) * 2021-02-03 2023-10-01 Skybio Llc A chemically conjugated carrier for bioactive drugs with low hydrophobicity into the central nervous system

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21366A (en) 1858-08-31 Valve-cock
USRE26271E (en) * 1967-09-26 Reductive alkylation process
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3043875A (en) * 1959-10-22 1962-07-10 Pfizer & Co C Halogenated tetracycline derivatives and processes for their preparation
FR1430859A (es) * 1960-05-23 1966-05-25
US3338963A (en) * 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
US3862225A (en) * 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3148212A (en) * 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
USRE26253E (en) * 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US3609188A (en) * 1964-10-29 1971-09-28 American Cyanamid Co 4-dedimethylamino-4-substituted-amino-6-demethyltetracyclines
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3397230A (en) * 1966-03-14 1968-08-13 American Cyanamid Co Nitration of tetracyclines
US3433834A (en) * 1966-03-14 1969-03-18 American Cyanamid Co Nitration of 11a-chloro tetracyclines
US3341585A (en) * 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
NL6607516A (es) 1966-05-31 1967-12-01
US3403179A (en) * 1967-01-10 1968-09-24 American Cyanamid Co Novel 7-(1, 2-bis-substituted-hydrazino)-tetracyclines and methods of preparing same
US3373196A (en) * 1967-03-21 1968-03-12 American Cyanamid Co 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines
US3518306A (en) * 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US3579579A (en) * 1968-04-18 1971-05-18 American Cyanamid Co Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3795707A (en) * 1970-12-28 1974-03-05 Rachelle Labor Italia Spa Manufacture of alpha-6-deoxytetracyclines
CA999855A (en) * 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2527568A1 (de) 1974-06-25 1976-01-15 Farmaceutici Italia Verfahren zur herstellung von alkyltetracyclinen und neue tetracyclinderivate
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) * 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4946453A (en) * 1988-04-14 1990-08-07 Monson Demetrius A Weight reducing athletic garment
US5388391A (en) 1988-12-19 1995-02-14 Parker; Richard D. Apparatus and process for packaging biohazardous wastes
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5281628A (en) * 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
DE122006000058I2 (de) 1991-10-04 2007-09-13 Wyeth Corp 7-Substituierte-9-substituierte Amino-6-Demethyl-6-Deoxy-Tetracycline
US6756365B2 (en) * 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5328902A (en) * 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
SG47520A1 (en) * 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5442059A (en) * 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5420272A (en) * 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5284963A (en) * 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
DE69304292T2 (de) 1992-11-17 1997-01-02 Univ New York Tetracycline inclusive nicht antimicrobiel wirksame, chemisch modifizierte Tetracycline hemmende exzessive Kollagenquervernetzung bei Diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) * 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
AU1279095A (en) 1994-02-17 1995-09-04 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US6063775A (en) * 1997-04-29 2000-05-16 Berman; Charles L. Retardation of metalloproteinase incidental to HIV and/or AIDS
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
JP2002501026A (ja) * 1998-01-23 2002-01-15 トルスティーズ オブ トゥフツ カレッジ 薬学的に活性の化合物及びその利用法
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
JP2002525299A (ja) * 1998-09-28 2002-08-13 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク 新規白内障形成抑制剤
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
ATE336238T1 (de) * 1998-11-18 2006-09-15 Collagenex Pharm Inc Neue 4-dedimethylaminotetracyclinderivate
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6500812B2 (en) * 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6849615B2 (en) * 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US8106225B2 (en) * 1999-09-14 2012-01-31 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
PT1240133E (pt) * 1999-09-14 2006-07-31 Tufts College Processos para preparar tetraciclinas substituidas com quimicas baseadas em metais de transicao
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
CA2397863A1 (en) * 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
WO2001070776A2 (en) * 2000-03-10 2001-09-27 Trustees Of Tufts College Nimr compositions and their methods of use
WO2001074761A1 (en) * 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US6642270B2 (en) * 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
AU2000254942A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
WO2001098236A2 (en) * 2000-06-16 2001-12-27 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20020128237A1 (en) * 2000-06-16 2002-09-12 Nelson Mark L. 7-N-substituted phenyl tetracycline compounds
US20050143353A1 (en) * 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
ATE504562T1 (de) * 2000-07-07 2011-04-15 Tufts College 7-, 8- und 9-substitutierte tetracyclinverbindungen
SI1301467T1 (sl) * 2000-07-07 2007-02-28 Tufts College 9-substituirane minociklinske spojine
US7094806B2 (en) * 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
IL153672A0 (en) * 2000-07-07 2003-07-06 Tufts College 7-substituted tetracycline compounds
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1368305B1 (en) * 2001-03-13 2008-08-13 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
AU2002250331A1 (en) * 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
EP1241160A1 (en) * 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
CA2457234A1 (en) * 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
WO2002072031A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
DE60212613T2 (de) * 2001-04-05 2007-05-24 Collagenex Pharmaceuticals, Inc. Doxycyclin zur behandlung von akne
DE60235083D1 (de) * 2001-04-24 2010-03-04 Paratek Pharm Innc Substituierte tetracyclin-verbindungen zur behandlung von malaria
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
JP2004537544A (ja) * 2001-07-13 2004-12-16 パラテック ファーマシューティカルズ インコーポレイテッド 標的治療活性を有するテトラサイクリン化合物
US7075582B2 (en) * 2001-07-13 2006-07-11 Paratek Pharmaceuticals, Inc. Methods for identifying and using MarR family polypeptide binding compounds
CA2462572C (en) * 2001-10-05 2008-11-18 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
ES2551708T3 (es) * 2002-01-08 2015-11-23 Paratek Pharmaceuticals, Inc. Compuestos de 4-desdimetilamino tetraciclina
EP1482926A4 (en) * 2002-03-08 2006-04-12 Paratek Pharm Innc AMINO METHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003079984A2 (en) * 2002-03-21 2003-10-02 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
EP1648859B1 (en) * 2003-07-09 2013-02-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
US7786099B2 (en) * 2004-01-15 2010-08-31 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP2269991A3 (en) * 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2006047671A2 (en) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
JP2009502809A (ja) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法

Also Published As

Publication number Publication date
US20060089336A1 (en) 2006-04-27
EP2311797A1 (en) 2011-04-20
JP2010111690A (ja) 2010-05-20
US20160324880A1 (en) 2016-11-10
JP2015063557A (ja) 2015-04-09
US7056902B2 (en) 2006-06-06
EP2311799A1 (en) 2011-04-20
EP2995610A1 (en) 2016-03-16
EP2322501A1 (en) 2011-05-18
EP2311798A1 (en) 2011-04-20
EP2311796A1 (en) 2011-04-20
AU2003235759A1 (en) 2003-07-24
EP2322501B1 (en) 2015-08-05
JP2005514410A (ja) 2005-05-19
EP1474380A4 (en) 2007-04-18
JP2017178962A (ja) 2017-10-05
US20040157806A1 (en) 2004-08-12
US9278911B2 (en) 2016-03-08
AU2003235759A8 (en) 2003-07-24
US20150105355A1 (en) 2015-04-16
EP1474380A2 (en) 2004-11-10
WO2003057169A3 (en) 2003-12-04
WO2003057169A2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
CN114072411B (zh) 作为Wee1抑制剂的嘧啶衍生物
Sun et al. Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation
CN118871436A (zh) 可用作抗癌剂的吡唑基衍生物的合成方法
EP3632910A1 (en) Lactam compound as fxr receptor agonist
US12371416B2 (en) Compounds for inhibition of fibroblast activation protein
SU1416057A3 (ru) Способ получени пиридиловых соединений или их кислотно-аддитивных солей,или сложных эфиров,или амидов
ES2585287T3 (es) Derivado de pirazolopirimidina
Zhang et al. Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y14 receptor antagonists
Saghiyan et al. Asymmetric synthesis of β-heterocycle substituted l-α-amino acids
CA2882119A1 (en) Solid forms of an antiviral compound
PT90339B (pt) Processo para a preparacao de benzodiazepinas, uteis em terapia, e de intermediarios para esse fim
McCulloch et al. Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives
CZ283731B6 (cs) Galanthaminové deriváty, způsob jejich přípravy a jejich použití jako léčiv
BRPI0720465B1 (pt) processo para produção de composto de precursor para composto orgânico marcado com halogênio radioativo
Hua et al. Syntheses and bioactivities of tricyclic pyrones
WO2008092335A1 (en) Novel vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives
Guerrero et al. Oxidative radical cyclization on enamide systems using n-Bu3SnH and dilauroyl peroxide
WO1994020106A1 (fr) Renforceur de sensibilite pour agent antineoplasique
TW202214658A (zh) 三氮唑並[1,5-a]吡嗪製備方法及其應用
Costero et al. Synthesis of a new allosteric carrier containing three conformationally related subunits
ES2222351T3 (es) Isolucion de isomeros de n-(n-(3,3-dimetilbutil)-l-alfa-aspartil)-l-fenilalanina-1-metilester por medio de iones metalicos.
ES2911447T3 (es) Resolución de derivados de diazaspiro[4.5]decano ópticamente activos
NAKAGAWA et al. Synthesis of the imidazo [1, 2-a] indole-spirolactone ring system by oxidative double cyclization. A synthetic approach to tryptoquivalines
CN121285542A (zh) Hdac1/2选择性抑制剂及其用途
Takahashi et al. Photochemistry of diazonium salts. Syntheses of 2, 4-difluoroimidazole-5-carboxylic acid and related compounds